
About
Mr. Orwin joined the Seagen Board of Directors in January 2014. With many years of experience as a senior executive at leading pharmaceutical and biotechnology companies, he brings a strong understanding of the industry and the challenges we must meet to continue developing and commercializing product candidates.
Mr. Orwin is the President and Chief Executive Officer of Atreca, Inc. Previously, he was the Chief Executive Officer of Relypsa, Inc., now an affiliate of Vifor Pharma AG. Mr. Orwin also held multiple leadership roles at Affymax, Inc., including Chief Executive Officer, President, and Chief Operating Officer. Earlier in his career, he led the BioOncology Business Unit at Genentech, Inc. and was the Franchise Vice President of Tibotec Therapeutics at Johnson & Johnson.
Mr. Orwin holds an M.B.A. from the Stern School of Business at New York University and a B.A. in Economics from Rutgers University. He serves as Chairman of the Board for AnaptysBio, Inc. and as a member of the board of directors for Atreca, Inc. and Travere Therapeutics, Inc.
Personal Details
Qualifications & Experience
Other directorships (state)
(only entities turnover at least $5m p/a)
Working history
Member
Johnson and JohnsonAppointed Date: 01/07/2001
Date Resigned: 01/12/2004
Industry: Healthcare
View Company
Committee/s
| Company | Committee | Role | Appointment Date | Resignation Date |
|---|---|---|---|---|
| Seattle Genetics | Other (specify) | Member | 01/01/2014 | |
| Seattle Genetics | Board | Member | 01/01/2014 |